Gilead Sciences (GILD) has decided to halt the clinical development of an inhalational formulation of its blockbuster COVID-19 drug remdesivir.Speaking at the conference call...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Friday, July 30th. Please refresh for updates.Amazon (NASDAQ:AMZN) stock fell 6.9% after the e-commerce...
IGM Biosciences (IGMS) has appointed Chris H. Takimoto as the company’s new chief medical officer, effective July 29.A veteran in the industry for 30 years in cancer research...
After its more than 450% surge during 2020, the meteoric rally in Moderna (NASDAQ:MRNA) shares continues this year. The gains—propelled by the biotech's breakthrough vaccine...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Strong Sell | Neutral | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Buy | Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Neutral | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 504.20 | 508.40 | 497.40 | -3.80 | -0.75% | 1.80M | London | |||
| 295.00 | 295.00 | 268.15 | +15.00 | +5.36% | 4.15K | London | |||
| 45.63 | 46.33 | 45.38 | -0.56 | -1.22% | 164.24M | London | |||
| 8,268.00 | 8,281.00 | 8,180.00 | -9.0 | -0.11% | 2.11M | London | |||
| 7,882.00 | 7,944.00 | 7,726.00 | -28.0 | -0.35% | 205.21K | London | |||
| 397.45 | 400.35 | 394.00 | -3.55 | -0.89% | 18.53M | London | |||
| 3,450.00 | 3,490.00 | 3,412.00 | -32.00 | -0.92% | 168.65K | London | |||
| 1,073.00 | 1,073.00 | 1,054.50 | +13.00 | +1.23% | 1.53M | London | |||
| 289.20 | 293.95 | 287.85 | -6.45 | -2.18% | 39.84M | London | |||
| 106.00 | 108.40 | 106.00 | -2.00 | -1.85% | 801.31K | London | |||
| 168.10 | 178.56 | 167.40 | -13.54 | -7.45% | 40.49M | London | |||
| 142.60 | 144.20 | 139.70 | +0.90 | +0.64% | 937.54K | London | |||
| 44.84 | 46.75 | 44.84 | -1.87 | -4.00% | 6.84M | London | |||
| 267.60 | 268.60 | 263.10 | +3.00 | +1.13% | 14.09M | London | |||
| 679.40 | 681.00 | 672.60 | +0.40 | +0.06% | 1.50M | London |
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
